Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,006 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

NCT01782963

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • John Hopkins University Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
View Trial Details
Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Mayo Clinic Rochester, Minnesota, United States
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Institute East Melbourne, Victoria, Australia
  • Frankston Hospital Frankston, Victoria, Australia
View all 94 locations
View Trial Details
Completed

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

NCT00896454

Conditions
Blood Protein Disorders, Breast Cancer, Breast Diseases, +77 more
Locations
  • Research Site Encinitas, California, United States
  • Research Site New Haven, Connecticut, United States
  • Research Site Salisbury, Maryland, United States
  • Research Site Dearborn, Michigan, United States
View all 24 locations
View Trial Details
Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03000452

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • Cancer Center of Central Connecticut Southington, Connecticut, United States
  • Parkview Research Center Fort Wayne, Indiana, United States
  • Indiana University Cancer Center Indianapolis, Indiana, United States
View all 25 locations
View Trial Details
Completed

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

NCT00231166

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102 Boston, Massachusetts, United States
  • St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer New York, United States
  • Oregon Health Sciences University Portland, Oregon, United States
  • University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions